These findings have not only provided us with initial understanding into the causative role of anti-nephrin autoantibodies in the development of podocytopathies but also justified the efficacy of B cell depletion therapies, which are being studied in clinical trials involving patients with nephrotic syndrome [29,30]. This evidence concerns the gene NPHS1 and nephrotic syndrome.